Country Access Report
Panama maintains a restrictive statutory and enforcement approach to classic psychedelics (psilocybin, MDMA, DMT, mescaline, 2C‑series, etc.), which remain criminalized outside of authorized research. Ketamine is an established medical anesthetic and is procured and used within the public health system; however, the proprietary esketamine nasal spray (Spravato) does not appear in public Panamanian regulator procurement/communication records and there is no publicly available evidence of national registration or public reimbursement for Spravato as of February 20, 2026. Access to nearly all classic psychedelics is limited to participation in approved clinical trials or illicit markets.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled substance under Panamanian drug‑scheduling and criminal law, with no authorized medical use outside of approved clinical research. This legal characterization and enforcement interpretation is reflected in recent country‑level legal summaries and market analyses that describe possession and distribution as subject to criminal penalties. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of MDMA being available for medical prescription or covered by public or private insurance in Panama outside of formal, approved trials. [1]
Compound Access
Esketamine (Spravato®) is an internationally licensed psychiatric medicine in certain jurisdictions (e.g., approved by the U.S. FDA for TRD and depressive symptoms with acute suicidal ideation/behavior) but there is no public evidence in Panamanian official procurement or Ministry of Health communications that esketamine (Spravato) is registered, procured, or reimbursed by Panama’s public system as of February 20, 2026. For context, Spravato’s approval and REMS requirements are described by the FDA. [1] Additionally, searches of Panama public procurement listings and Ministry of Health safety communications show routine procurement and clinical guidance references for ketamine (the racemate) rather than esketamine (Spravato), and there is no public specialty‑pharmacy/coverage policy listing for Spravato in Panamanian government procurement portals. [2] [3]
Compound Access
Ketamine (racemic ketamine) is an established medical anesthetic and analgesic in Panama’s health system; it appears on public procurement records and is discussed in Ministry of Health safety reviews, indicating routine legitimate clinical use (hospital anesthetic, emergency, and procedural settings). Panama’s public procurement portal includes tenders and purchase records for ketamine for public hospitals, demonstrating government purchasing for medical use. Public insurance coverage in Panama (through the social security/integrated public system) will cover medical care delivered in the public hospitals where ketamine is used for approved indications (anesthesia, analgesia), but there is no evidence public insurance reimburses private, off‑label ketamine‑based psychiatric treatment clinics as a standard covered benefit. Clinical use for psychiatric indications (e.g., IV ketamine for depression) would generally be considered off‑label and billed through the delivering institution or as private‑pay, and coverage decisions would vary by insurer and clinical setting. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public framework authorizing traditional or medical DMT use outside research protocols. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no public regulatory pathways for clinical or religious exemptions in Panama documented in public legal summaries. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no publicly listed, regulated ibogaine treatment clinics in Panama; individuals typically travel to other countries for clinic‑based ibogaine programs. International overviews of ibogaine legal status note wide variation across countries and highlight that many governments do not permit medical use outside tightly regulated research or do not explicitly authorize clinical programs. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws (because of the presence of DMT) with no recognized general legal medical or religious exemption in Panamanian statute or public guidance; authorized use would be limited to approved research. Panama does not have a documented nationwide religious exemption permitting sacramental ayahuasca use in the same manner as some jurisdictions in South America. [1] [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and cacti containing mescaline) are not covered by any medical reimbursement program in Panama and possession/trafficking carry criminal penalties. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family and other substituted phenethylamines are treated as illicit controlled substances in Panama and are subject to criminal enforcement. [1]
Last updated 2 Mar 2026. Source links come from the medical access guide.